AMLX logo

Amylyx Pharmaceuticals Inc. (AMLX)

$27.52

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AMLX

Market cap

$3.54B

EPS

-1.42

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

-0.080021

Price on AMLX

Previous close

$27.80

Today's open

$27.50

Day's range

$26.61 - $27.66

52 week range

$10.83 - $41.14

Profile about AMLX

CEO

Joshua Cohen

Employees

136

Headquarters

Cambridge, MA

Exchange

Nasdaq Global Select

Shares outstanding

128562904

Issue type

Common Stock

AMLX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on AMLX

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript

news source

Seeking Alpha • Nov 15, 2026

news preview

Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.

news source

Business Wire • Nov 14, 2026

news preview

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical Officer Dan Monahan - Chief Commercial Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Founder, Co-CEO & Director Conference Call Participants Jacob Ormes - TD Securities Equity Research Seamus Fernandez - Guggenheim Securities, LLC, Research Division Geoffrey Meacham - Citigroup Inc. Exchange Research Marc Goodman - Leerink Partners LLC, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Samuel Lee - Mizuho Securities USA LLC, Research Division Dina Ramadane - BofA Securities, Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Christopher Chen - Robert W.

news source

Seeking Alpha • Nov 6, 2026

news preview

Amylyx Pharmaceuticals Q3 Earnings Call Highlights

Amylyx Pharmaceuticals NASDAQ: AMLX plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027 following positive late-stage trial results.

news source

MarketBeat • Nov 5, 2026

news preview

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.

news source

Business Wire • Nov 5, 2026

news preview

Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.

news source

Business Wire • Nov 4, 2026

news preview

Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences.

news source

Business Wire • Nov 3, 2026

news preview

Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026.

news source

Business Wire • Nov 2, 2026

news preview

11 Stocks Most Likely to See a Short Squeeze Rally

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.

news source

Schaeffers Research • Oct 12, 2026

news preview

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.

news source

Business Wire • Oct 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Amylyx Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Amylyx Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AMLX on M1